Status:
RECRUITING
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
Lead Sponsor:
Celltrion
Conditions:
Non Squamous Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with prev...
Eligibility Criteria
Inclusion
- Stage IV, non squamous NSCLC
- Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
- Have at least 1 measurable lesion per RECIST version 1.1
Exclusion
- Have predominantly squamous cell histology NSCLC.
- Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin
Key Trial Info
Start Date :
January 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
606 Patients enrolled
Trial Details
Trial ID
NCT06939595
Start Date
January 30 2025
End Date
July 1 2028
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ltd "Institute of Clinical Oncology"
Tbilisi, Georgia